Jun 13, 2008 - Gilead Sciences, Inc. (Nasdaq:GILD) announced results from an interim analysis of 12-month data from its open-label, Phase III AIR-CF3 (006) study of aztreonam lysine for inhalation, an investigational therapy in development for the treatment of people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa). AIR-CF3 is an ongoing, multi-center study designed to evaluate the safety of repeated exposure to aztreonam lysine in cystic fibrosis patients who originally participated in the pivotal Phase III AIR-CF1 (007) or AIR-CF2 (005) studies... Gilead's Press Release -
Jun 23, 2008
Gilead : Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Jun 13, 2008 - Gilead Sciences, Inc. (Nasdaq:GILD) announced results from an interim analysis of 12-month data from its open-label, Phase III AIR-CF3 (006) study of aztreonam lysine for inhalation, an investigational therapy in development for the treatment of people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa). AIR-CF3 is an ongoing, multi-center study designed to evaluate the safety of repeated exposure to aztreonam lysine in cystic fibrosis patients who originally participated in the pivotal Phase III AIR-CF1 (007) or AIR-CF2 (005) studies... Gilead's Press Release -
